We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 0.09% | 1,637.50 | 1,637.50 | 1,638.00 | 1,656.00 | 1,635.00 | 1,642.00 | 2,895,479 | 15:40:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.77 | 67.85B |
TIDMGSK
RNS Number : 7360T
GlaxoSmithKline PLC
16 October 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Ms E Walmsley === ======================== ================================================ b) Position/status Chief Executive Officer === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 1,605.036 ------------ ---------- GBP15.2750 831.931 ------------ ---------- GBP15.2750 2,740.030 ------------ ---------- GBP15.2750 4,439.830 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 9,616.827 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr R G Connor === ======================== ================================================ b) Position/status President, Global Manufacturing & Supply === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 1,249.200 ------------ ---------- GBP15.2750 1,600.015 ------------ ---------- GBP15.2750 1,529.167 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 4,378.382 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr L Debruyne === ======================== ================================================ b) Position/status President, Global Vaccines === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 319.540 ------------ ---------- GBP15.2750 402.745 ------------ ---------- GBP15.2750 1,147.102 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 1,869.387 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr S Dingemans === ======================== ================================================ b) Position/status Chief Financial Officer === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 2,716.836 ------------ ---------- GBP15.2750 2,942.442 ------------ ---------- GBP15.2750 2,427.360 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 8,086.638 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr N Hirons === ======================== ================================================ b) Position/status SVP, Global Ethics & Compliance === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 605.675 ------------ ---------- GBP15.2750 660.007 ------------ ---------- GBP15.2750 563.370 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 1,829.052 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================= a) Name Mr B McNamara === ======================== =============================================== b) Position/status CEO, GSK Consumer Healthcare === ======================== =============================================== c) Initial notification/ Initial notification amendment === ======================== =============================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================= a) Name GlaxoSmithKline plc === ======================== =============================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =============================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================= a) Description of American Depositary Shares ('ADSs') the financial ISIN: US37733W1053 instrument === ======================== =============================================== b) Nature of the Increase in notional interest in ADSs following transaction the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan. === ======================== =============================================== c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- $41.02 415.800 --------- ---------- $41.02 83.187 --------- ---------- $41.02 641.729 --------- ---------- $41.02 1,036.064 --------- ---------- === ======================== =============================================== d) Aggregated information Aggregated volume Price 2,176.780 $41.02 === ======================== =============================================== e) Date of the transaction 2017-10-12 === ======================== =============================================== f) Place of the n/a transaction === ======================== =============================================== 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr D S Redfern === ======================== ================================================ b) Position/status Chief Strategy Officer === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 993.680 ------------ ---------- GBP15.2750 1,160.005 ------------ ---------- GBP15.2750 1,094.561 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 3,248.246 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Ms C Thomas === ======================== ================================================ b) Position/status SVP, HR === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 1,324.911 ------------ ---------- GBP15.2750 1,460.009 ------------ ---------- GBP15.2750 1,207.230 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 3,992.150 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ============================================================================ a) Name Mr P C Thomson === ========================== ================================================ b) Position/status President, Global Affairs === ======================== ================================================== c) Initial notification/ Initial notification amendment === ========================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ============================================================================ a) Name GlaxoSmithKline plc === ========================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ========================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ============================================================================ a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ========================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ========================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 766.560 ------------ ---------- GBP15.2750 840.010 ------------ ---------- GBP15.2750 756.529 ------------ ---------- === ========================== ================================================ d) Aggregated information Aggregated volume Price 2,363.099 GBP15.2750 === ========================== ================================================ e) Date of the transaction 2017-10-12 === ========================== ================================================ f) Place of the n/a transaction === ========================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================= a) Name Mr D E Troy === ======================== =============================================== b) Position/status SVP & General Counsel === ======================== =============================================== c) Initial notification/ Initial notification amendment === ======================== =============================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================= a) Name GlaxoSmithKline plc === ======================== =============================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =============================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================= a) Description of American Depositary Shares ('ADSs') the financial ISIN: US37733W1053 instrument === ======================== =============================================== b) Nature of the Increase in notional interest in ADSs following transaction the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan. === ======================== =============================================== c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- $41.02 1,132.956 --------- ----------
$41.02 1,314.438 --------- ---------- $41.02 1,154.472 --------- ---------- === ======================== =============================================== d) Aggregated information Aggregated volume Price 3,601.866 $41.02 === ======================== =============================================== e) Date of the transaction 2017-10-12 === ======================== =============================================== f) Place of the n/a transaction === ======================== =============================================== 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Dr P J T Vallance === ======================== ================================================ b) Position/status President, R&D === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 2,755.819 ------------ ---------- GBP15.2750 3,400.038 ------------ ---------- GBP15.2750 3,138.824 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 9,294.681 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mrs V A Whyte === ======================== ================================================ b) Position/status Company Secretary === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP15.2750 169.685 ------------ ---------- GBP15.2750 160.363 ------------ ---------- GBP15.2750 150.569 ------------ ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 480.617 GBP15.2750 === ======================== ================================================ e) Date of the transaction 2017-10-12 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEQLFFDBFXFBX
(END) Dow Jones Newswires
October 16, 2017 11:40 ET (15:40 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions